Funding for this research was provided by:
Ministry of Health of the People's Republic of China (TC 277/2013)
Fundação de Amparo à Pesquisa do Estado de Minas Gerais (BPD-00205-13)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (167663/2013-5)
PANLAR Rheumatology Award
Text and Data Mining valid from 2019-03-14
Received: 2 September 2018
Accepted: 25 February 2019
First Online: 14 March 2019
Ethics approval and consent to participate
: This study was approved by the Ethics Committee for studies with human subjects at Instituto René Rachou FIOCRUZ (CPqRR # 180911). All subjects gave written informed consent in accordance with the Declaration of Helsinki.
: Not applicable.
: Two authors (MM and SL) are employees at the 17DD-YF vaccine manufacturer (Bio-Manguinhos, Fundação Oswaldo Cruz), and five authors work in other units of Fundação Oswaldo Cruz (ACC, VP, LA, ATC, and OM). Bias from competing interest was prevented by (1) collaboration of three clinical physicians (CF, AO, and LM) with experience in rheumatic diseases from Universidade de Brasília, (2) one official member from the Brazilian Health Ministry (CD) with experience in vaccine epidemiological vigilance and policies, (3) two independent professionals working as undergraduate students (LF and IR), and (4) two post-doc researchers (JC and KT) working in the field of infectious diseases. The FIOCRUZ extramural coworkers contributed with the critical overview of the study design, volunteers’ immunization and medical care, blood sample collection, blind sample handling and processing, data collection, statistical analysis, and data interpretation.The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.